J&J hikes US prices for a basket of drugs, including certain top-sellers | Reuters
As Democratic members of Congress proposed legislation to curb soaring drug prices on Thursday, the world’s biggest drugmaker by revenue Johnson & Johnson $JNJ raised prices for about two dozen of its prescription medicines, adding to the hundreds of price hikes already initiated by various drugmakers in 2019.
Most of the increases on J&J’s drugs — including top-sellers psoriasis drug Stelara, cancer drug Zytiga and blood thinner Xarelto — were between 6% and 7%, according to a report by Reuters, citing data from Rx Savings Solutions, which helps health plans, employers and employees seek cheaper prescription medicines.
The Band-Aid maker is not planning to raise the prices on any more of its drugs this year, J&J told Reuters. Among large biopharma companies, J&J is one of the least dependent on drug price hikes for growth, according to a recent analysis published by Leerink.
Allergan $AGN, Pfizer $PFE, Bristol-Myers Squibb $BMY, Biogen $BIIB, Sanofi $SNY, Novo Nordisk $NVO and other top drugmakers all greeted 2019 with price hikes, although data suggest that in general, drugmakers are slowing the size and frequency of price hikes as political, media and public scrutiny into pricing intensifies.
Read complete article here:
J&J hikes US prices for a basket of drugs, including certain top-sellers — Reuters – Endpoints News.
Connect
Follow via RSS feed or on the following social media platforms.